Summary
- Zydus Lifesciences and Formycon's Biologics License Application for FYB206, a biosimilar to Keytruda®, has been accepted for review by the USFDA.
- This marks the first publicly announced acceptance of such an application, with a review expected to conclude by the third quarter of 2027.
- The innovative development pathway bypassed a comparative Phase III efficacy trial, allowing for accelerated progress and reduced investment.
- The collaboration aims to enhance access to affordable cancer treatments, with analysts keenly observing the implications for the biosimilars market.
Join the discussion — sign up to comment, upvote, and save articles.